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ABSTRACT 
OBJECTIVE: The objective of this selective EBM review is to determine “Are antibiotics, other 
than roxithromycin, an effective way to manage joint pain in rheumatoid arthritis?” 
 
STUDY DESIGN: Review of three double-blind, randomized-controlled studies published in 
English between 2001-2007. 
 
DATA SOURCES: Three randomized controlled trials published between 2001 and 2007 were 
found using PubMed/MEDLINE and Cochrane databases. 
 
OUTCOMES MEASURED: Clinical outcome for all three studies used American College of 
Rheumatology (ACR) criteria, which assesses joints for swelling and tenderness. 
 
RESULTS: In the Odell et al.1 study, at 24 months 28 participants did meet the ACR50 criteria. 
In treatment group 1, 18 of 30 (60%) participants and 10 of 30 (33%) participants in treatment 
group 2 met the ACR50 criteria, (P=0.04). Ogrendik et al.2 34% of participants in the antibiotic 
treatment group had an ACR50 response at 6 months versus 10% in treatment group 2. Ogrendik 
et al.3 found that 34.2% of participants in the antibiotic treatment group had an ACR50 response 
at 6 months compared to 7.9% in treatment group 2. 
 
CONCLUSIONS: The statistical results from all three studies found that antibiotics had greater 
efficacy in treating pain in rheumatoid arthritis compared to other interventions or placebo. It 
would be beneficial to study the effects of antibiotic use in patients who had chronic RA. 
 
KEYWORDS: antibiotics, rheumatoid arthritis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
INTRODUCTION 
 
 Rheumatoid arthritis is a chronic autoimmune disease that can potentially lead to 
permanent disability.3 The disease process begins when immune cells begin to release chemicals 
that target the synovium and destroy cartilage and bone. The destruction of cartilage leads to 
joint stiffness, tenderness, swelling, and limited mobility.  While RA particularly affects the 
smaller joints of the hands and wrist, it can also affect other joints and organs in more advanced 
stages of the disease process.7 This paper evaluates three double-blind, randomized controlled 
studies that look at the effectiveness of antibiotics, other than roxithromycin, in the management 
of joint pain in RA.   
 RA is a serious autoimmune disease that can progress to permanent destruction and 
limited mobility of certain joints, especially in the hands and wrists.6 RA affects approximately 
one million Americans, 75% of those being women.7 The incidence of RA in the United States 
has significantly decreased since the 1960s, but it continues to be the most common type of 
autoimmune arthritis.8 Women are affected in the 4th and 5th decades, whereas men are affected 
later in the 5th and 6th decades. In 2013, approximately $19 billion was spent on RA treatment 
(medications, hospitalizations, office visits, and physical therapy), which amounts to about 
$30,000 a year per patient. The costs for RA treatment is expected to increase over the next 4 
years due to the development of new medications; newer medications mean increased costs.6 Per 
2007 data, 2.6 million annual doctor’s visits were attributed to RA, and 2012 data showed 
approximately 9,100 RA related hospitalizations.9 
 The exact etiology of RA is unknown. However, there are many risk factors and 
comorbidities that are associated with RA. It is thought that a combination of environmental and 
genetic factors contributes to the incidence of RA. Modifiable risk factors include: smoking, oral 
contraceptives, hormone replacement therapy, breastfeeding, and irregular menses. Non-
modifiable risk factors include: genotypes HLA-DR4 and DRB1, age (40-60s), and sex 
(female).9 There are also several comorbidities associated with RA. Though the exact correlation 
between cardiovascular disease and RA is not fully understood, research has shown that with 
further progression of RA the higher the prevalence of CVD. Also, infections, such as 
tuberculosis, are also closely associated with RA.9 Data has shown up to ¼ of deaths in RA 
patients are related to infections. Researchers are unsure if the infections associated with RA are 
due to immune system failure or immunosuppressant used for treatment.9 
 Synthetic disease modifying antirheumatic drugs (DMARD) are the initial drug of choice 
for RA, specifically methotrexate. Other synthetic DMARDs include sulfasalazine, leflunomide, 
tofactinib, and hydroxychloroquine.4 There are also biological DMARDs used in the treatment of 
RA, which include: TNF inhibitors, abatacept, rituximab, and tocilizumab. Typically, DMARDs 
are most effective when used in combination with each other. The most common combination is 
methotrexate and a TNF inhibitor.4 Low dose corticosteroids are also used for 2-6 weeks until 
the biologic DMARD reaches its full efficacy.4 Combination DMARDs are currently the 
standard of care. Antibiotic treatment, alone or in combination with a DMARD, has been 
researched to determine their effectiveness at managing painful joints when used in early RA.   
OBJECTIVE 
The objective of this selective EBM review is to determine “Are antibiotics, other than 
roxithromycin, an effective way to manage joint pain in rheumatoid arthritis?” 
METHODS 
Participants in the 3 double-blinded randomized controlled studies reviewed for this 
paper included male/female adults who fulfilled American College of Rheumatology criteria. All 
3 studies evaluated participants based on ACR criteria. Participants in the O’Dell et al.1 study 
met the following criteria:19-70 years old, positive rheumatoid factor, duration of disease > 6 
weeks to <1 year, and active RA (ESR 28 mm/hr, morning stiffness >45 minutes, >8 tender 
joints, >3 swollen joints). Ogrendik et al.2 conducted a study with participants meeting the 
following criteria: 18-70 years old, disease duration less than 3 years, failed DMARD therapy 
(azathioprine, methotrexate, sulfasalazine, penicillamine, hydroxychloroquine, or injectable 
gold), active disease at enrollment (12+ tender joints, 10+ swollen joints) and one of the 
following ESR 28mm/hr, CRP > 2.0 mg/dl, or morning stiffness > 45 minutes. Ogrendik et al.3 
conducted a study with participants meeting the following criteria: currently taking methotrexate 
for at least 6 months, active disease (12+ tender joints, 10+ swollen joints), and at least one of 
the following: ESR >28 mm/hr or CRP 2.0 mg/dl.  
Interventions used in the above studies were: combination Minocycline 100 mg PO BID 
x 2 years and low dose prednisone (7.5mg or 5 mg per day) versus combination 
hydroxychloroquine 200 mg PO BID and low dose prednisone (O’dell et al.1), clarithromycin 
500 mg PO QD x 6 months versus placebo (Ogrendik et al. 2), and levofloxacin 500 mg PO QD 
x 6 months in combination with a stable dose of methotrexate either oral or subcutaneous versus 
placebo plus stable dose of methotrexate (Ogrendik et al.3). The primary outcome measured for 
all three studies was the reduction in the number of painful/tender joints after the appropriate 
intervention was administered. 
The clinical studies reviewed for this paper were found using Pubmed and Cochrane 
Database. All sources were peer-reviewed articles printed in English between 2001-2007, and 
keyword searches included: rheumatoid arthritis, minocycline, and antibiotics. Inclusion criteria 
for this paper were randomized controlled trials, double blinded trials, all of which focused on 
POEMs. The following were exclusion criteria for this paper: articles reviewing roxithromycin in 
the treatment of RA, peer-reviewed articles published prior to 2000, Cochrane systematic 
reviews, as well as previously published systematic reviews by former students. Statistics used in 
all three studies include: control event rate (CER), experimental event rate (EER), relative 
benefit increase (RBI), absolute benefit increase (ABI), number needed to treat (NNT) and p-
value. Table 1 (below) reports the demographics of each study used in this paper. 
 
Table 1. Demographics & Characteristics of Included Studies 
 
 
Study Type #pts Age Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Intervention 
O’dell, 
2001 (1) 
RCT 60 19-
70 
Pts who have had 
RA for at least 6 
weeks and fulfill 
ACR criteria. 
Pts who received 
previous disease 
modifying drugs, 
who received 
steroids in the last 
2 months, and 
women of 
childbearing age 
who were not on 
contraception. 
5 Minocycline 
100 mg BID vs. 
Hydroxychloro
quine 200 mg 
BID 
 
*both groups 
were on low 
dose prednisone 
7.5mg or 
5mg/day 
Ogrendik 
2007 (2) 
RCT 81 18-
70 
Pts who have 
active disease, 
defined as 12 or 
more tender joints, 
ten or more 
swollen joints, and 
at least 1 of the 
following: SED 
rate >28mm/h, 
morning stiffness 
>45mins, and 
disease longer than 
3 years. 
Pregnant women, 
elevated LFT and 
RFT, chronic 
infection, and 
allergic to ABX 
used in the study. 
9 500 mg of 
clarithromycin 
vs placebo 
Ogrendik 
2007 (3) 
RCT 76 >18 Pts who had been 
taking 
methotrexate for at 
least 6 months, 
active disease, 12+ 
tender joints. 
Pregnancy, serious 
infection, 
inadequate control 
of arthritis 
symptoms, 
impaired LFT and 
RFT, untreated 
HTN. 
6 500 mg 
levofloxacin vs 
placebo 
 
*both groups 
were given 
methotrexate 
15-25mg/week 
OUTCOMES MEASURED 
 The American College of Rheumatology (ACR) response is used in all three studies to 
assess the efficacy of the intervention. ACR response include the following criteria: 
tender/swollen joint count, acute phase reactant (such as sedimentation rate), patient assessment, 
physician assessment, VAS pain score, and disability/functional questionnaire. ACR 20, 50, and 
70 response were assessed in all three studies. This means that a person must have improved by 
20, 50, or 70% for the designated intervention to have been clinically effective. In the O’Dell et. 
al1 study, the intervention was minocycline 100 mg PO BID x 2 years plus low dose prednisone. 
Ogrendik et al.2,3 studies also measure ACR20, ACR50, and ACR70; interventions used in these 
two studies were Clarithromycin 500 mg PO QD x 6 months and Levofloxacin 500 mg PO QD x 
6 months plus methotrexate 15-25 mg daily, respectively. The ACR criteria were assessed using: 
Ritchie Articular Index, patient’s global assessment of disease activity with visual analog scale, 
pain assessed with visual analog scale, physician’s global assessment of disease activity, and 
Health Assessment Questionnaire (HAQ). The statistics reported or used in the articles were  
relative benefit increase (RBI), absolute benefit increase (ABI), numbers needed to treat (NNT), 
and P values. 
RESULTS 
 All three studies looked at the efficacy of antibiotic treatment for pain management in 
rheumatoid arthritis. Two studies compared the use of antibiotic treatment versus placebo, and 
the third study compared antibiotic treatment to hydroxychloroquine.  
 The double-blinded RCT by O’Dell et al.1 further detailed in Table 1, enrolled 60 
participants. Patients who had previously taken DMARDs, steroid therapy in the last 2 months, 
or women of childbearing age were excluded from this study.1 60 participants were randomly 
assigned to treatment group 1 or 2. Treatment group 1 refers to the minocycline intervention (100 
mg BID), and treatment group 2 refers to the hydroxychloroquine intervention (200 mg BID). 
Both treatment groups were started on prednisone 7.5mg/day or 5mg/day if they weighed <60kg 
and tapered down if they met ACR50 criteria at 12 months. ACR50 criteria was assessed using 
patient’s assessment of disease activity, physician’s global assessment of disease activity, tender 
joint and swollen joint count, HAQ, erythrocyte sedimentation rate, and patient’s assessment of 
pain on 100-mm visual analog scale. Using the Ritchie Articular Index, 38 joints were assessed 
for tenderness and swelling. At 24 months, 28 participants did meet the ACR50 criteria. In 
treatment group 1, 18 of 30 (60%) participants and 10 of 30 (33%) participants in treatment 
group 2 met the ACR50 criteria, (P=0.04). At the beginning of the study, participants in 
treatment group 1 had an average of 18.9 tender joints and an average VAS pain score of 5.13. 
At the completion of the study, those participants had an average of 6.8 tender joints and an 
average VAS pain score of 2.5. Patient’s initial global assessment in treatment group 1 was 4.7 
compared to 2.0 at 24 months. At 12 months, those who met ACR50 criteria began to taper off 
prednisone. At the end of the 2-year study, prednisone dosages were also assessed and doses 
were lower in treatment group 1 (0.81 mg/day) than treatment group 2 (3.21 mg/day), (P<0.01). 
Also, participants in treatment group 1 were more likely to be completely tapered off prednisone 
at 24 months, (P=0.03)1. 3 participants in treatment group 1 and 2 from treatment group 2 
withdrew due to adverse reactions. Adverse reactions from treatment group 1 included: 
fingernail discoloration, dizziness, and an erythematous rash, and in treatment group 2: reasons 
for withdrawal were rash and gastrointestinal distress.  
The 6-month randomized double-blind controlled study by Ogrendik et al.2 randomly 
assigned 81 participants to either treatment group 1 (500 mg clarithromycin per day) or treatment 
group 2 (placebo). Exclusion criteria for this study was the following: pregnant women, impaired 
hepatic enzyme tests, impaired renal function, chronic/recurrent infection, or history of allergic 
reactions to macrolides. Participants’ outcomes were assessed using the same criteria as Odell et 
al.1 to determine if they met ACR 20 and 50 response, but for the purposes of this paper ACR50 
response will be the focus. At the beginning of the study, treatment group 1 had an average of 30 
tender joints and a VAS pain score of 6.9. After 6-months, the average tender joint count for 
treatment group 1 was 11 and a VAS pain score of 3.2, (P<0.001).  Table 2 shows more 
participants in treatment group 1 (34%) had met ACR50 criteria after 6 months compared to 
those in the placebo group (10%), (P<0.001). 9 participants withdrew from the study due to 
unsatisfactory treatment/worsening of disease; 3 participants were from treatment group and 6 
were from treatment group 2. In treatment group 1, the major complaint was a metallic taste or 
dry mouth (46%), (P <0.001). Also, 10% of participants in treatment group 1 and 8% in 
treatment group 2 complained of GI pain, (P<0.001). 17% of treatment group 1 and 15% of 
treatment group 2 complained of headaches, (P<0.001). 
In the 6-month randomized double-blind controlled study, Ogrendik et al.3 looked at the 
efficacy of levofloxacin versus placebo. Exclusion criteria for this study was the following: 
pregnancy, serious infection, inadequate control of arthritis, impaired renal function, untreated 
HTN, other inflammatory diseases, and any other relevant systemic disease. 76 participants were 
randomly assigned to treatment group 1 (500mg levofloxacin daily) or treatment group 2 
(placebo). At baseline, treatment group 1 had an average tender joint count of 32 and a VAS pain 
score of 6.5. At 6 months, treatment group 1 average tender joint count was 10 and VAS pain 
score of 2.2, (P<0.001). Participants were assessed utilizing the same criteria as Ogrendik et al.2 
ACR 50 response was assessed after 6 months to determine the efficacy of levofloxacin versus 
placebo. At 6 months, treatment group 1 showed greater response per the ACR criteria. 5% of 
participants in treatment group 1 and 11% from treatment group 2 withdrew due to unsatisfactory 
response to their intervention. There were no serious adverse events reported in this study. The 
more frequent complaint from treatment group 1 was gastrointestinal pain (15.6%) compared to 
treatment group 2 (5.3%), (P=0.05). Other adverse events included: nausea, vomiting, diarrhea, 
headache, and dry mouth. Overall, levofloxacin was well tolerated among participants.3 
Table 2. Comparison of ACR50 Criteria Between Treatment Group 1 and 2 
 
 Table 3 details relative benefit increase (RBI), absolute benefit increase (ABI), numbers 
needed to treat (NNT), and P values for each of the three studies used in this paper. P value 
signifies the probability that the outcome was due to chance. If the p value was less than 0.5, 
then it is unlikely the outcome was due to chance. All three studies had P values <0.5 (P=0.04, 
<0.001, 0.001, respectively). Also, NNT ranged between 3 and 5, signifying the number of 
patients that would need to be treated to prevent 1 adverse event.  
Table 3. O’Dell study: v. Hydroxychloroquine 
 
Study ACR 50  
Treatment Group 1 
% 
Antibiotic 
 
P-value 
Treatment Group 1 
 
ACR 50 
Treatment Group 2 
% 
P- value 
Treatment Group 2 
O’dell et al.1 60 
  
p=0.04 33 
 
p=0.04 
Ogrendik et al.2 34 
 
P<0.001 10 
 
P<0.001 
Ogrendik et al. 3 34.2 
 
P<0.001 7.9 
 
P<0.001 
Study CER 
HCQ 
EER 
minocycline 
RBI ABI NNT P value 
O’dell et al.1 0.33 0.60 0.82 0.27 4 P=0.04 
Ogrendik et al.2 0.10 0.34 2.4 0.24 5 P<0.001 
Ogrendik et al.3 0.79 0.34 2.14 0.40 3 P<0.001 
DISCUSSION 
   
 In Odell et al.,1 combination minocycline and prednisone had more success in controlling 
pain compared to combination hydroxychloroquine and prednisone. Minocycline is often used in 
treatment of acne, cellulitis, as well as the treatment of RA. Contraindications to minocycline 
include a previous allergic reaction or sensitivity to it. Adrenal suppression can be a possible side 
effect of prednisone with long term use.4 
  Also, in Ogrendik et al.,2 clarithromycin had great efficacy in treating pain compared to 
placebo. Clarithromycin is a broad spectrum antibiotic that is often used for the treatment of 
upper respiratory infections, peptic ulcer disease, pneumonia, as well as skin infections. 4 
Contraindications to this antibiotic include: concomitant use with HMG-CoA reductase 
inhibitors (statins) or colchcine or in patients who are renally impaired.4  
 Statistical results from Ogrendik et al.3 study favored the use of levofloxacin. Black box 
warnings for this antibiotic include; tendon rupture, CNS effects, and peripheral neuropathy. It 
can also accentuate symptoms of myasthenia gravis. This fluoroquinolone is often used for 
pneumonia, UTI, and pyelonephritis.5  
Firstly, the sample size for each study was considerably small. The largest study included 
81 participants and the smallest was 60. Also, in the study that investigated clarithromycin, 
participants had an initial side effect of a metallic taste in their mouth. Researchers in this study 
presumed that the blinding in the studied was compromised at this point, because they believed 
that the taste was due to the antibiotic killing bacteria in the mouth.2 Also, GI side effects are 
common in the use of antibiotics.5 Blinding may have been compromised for this reason after 
researchers assessed for side effects throughout the study. Another limitation in 2 of the studies 
was the use of combination treatment; for this reason it was difficult to determine the exact 
efficacy of levofloxacin and minocycline. 
CONCLUSION 
 This paper reviewed three double-blind randomized controlled studies that investigated 
the significance of antibiotic use in the management of pain in rheumatoid arthritis. The 
statistical results from all three studies found that antibiotics had greater efficacy in treating pain 
in rheumatoid arthritis compared to other interventions or placebo. Other than increasing the 
population size to increase the validity and reliability of antibiotic use in the management of pain 
in RA, future studies should consider using a higher range for ESR and CRP cutoff. Using low 
values would be associated with earlier stages of RA. However, it would be beneficial to study 
the effects of antibiotic use in patients who had chronic RA. The treatment of RA with 
antibiotics will hopefully be explored in the future alone or in combination with DMARDs.  
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